InMed Pharmaceuticals Inc. filings document the regulatory record of a British Columbia pharmaceutical issuer with common shares listed on Nasdaq under INM. Its disclosures cover small-molecule drug development programs targeting CB1 and CB2 receptors, including INM-901 for Alzheimer's disease and programs in ocular and dermatological indications.
Recent filings include Current Reports on Form 8-K for financial results and business updates, material definitive agreements involving preferred investment options, at-the-market offering documentation, Nasdaq continued-listing compliance, shareholder voting matters, and exit or disposal activities related to BayMedica. The company's formal reports also address risk factors, capital structure, governance, and clinical or regulatory disclosures.
InMed Pharmaceuticals (INM) reported an administrative update. On October 10, 2025, the company announced the meeting, record date, and related details for its 2025 annual general and special meeting of shareholders, as reflected in a revised submission to Canada’s SEDAR system. The notice was furnished via an 8-K under Item 8.01, with the SEDAR filing listed as Exhibit 99.1.
InMed Pharmaceuticals (INM) appointed Neil Klompas to its board of directors, effective October 9, 2025, and increased the board size to five members. His term runs until immediately before the 2025 Annual General Meeting. The company noted there are no related party transactions or family relationships tied to his appointment.
Klompas will receive non-employee director compensation consistent with company policy, including an annual retainer of US$50,000, with potential additional amounts for committee service. InMed furnished a press release as Exhibit 99.1.
InMed Pharmaceuticals Inc. filed a current report to note that on September 23, 2025 it announced financial results for its fiscal year ending June 30, 2025 and gave a business update. The update covered its pharmaceutical drug development programs and the commercial segment of its wholly owned subsidiary, BayMedica, LLC. The related news release is furnished as Exhibit 99.1 under a Regulation FD disclosure and is not deemed filed or incorporated by reference unless specifically stated in another filing.
InMed Pharmaceuticals Inc. reported that on September 23, 2025 it announced the meeting date, record date and related details for its 2025 annual meeting of shareholders through a filing on Canada’s SEDAR system. The company is making that SEDAR disclosure available to U.S. investors as Exhibit 99.1 to this report.
The company states that the information in this report, including Exhibits 99.1 and 99.2, is being furnished rather than filed under the U.S. securities laws, which limits how it is treated for liability purposes and incorporation by reference into other securities filings.
InMed Pharmaceuticals Inc. (INM) 10-K highlights key operational progress, financing and risks. The company reported continued operating losses with a net loss widening to $8.69 million for the latest year and an accumulated deficit of about $117.2 million. Management states cash resources are sufficient into the fourth quarter of calendar 2026, but concluded there is substantial doubt about the company’s ability to continue as a going concern without additional financing. Commercial operations at BayMedica are producing some revenues tied to bulk rare cannabinoids, and the company received gross proceeds of approximately $5.0 million from a private placement and $6.2 million from share issuances under a SEPA during the year.
On the R&D side, INM-901 (Alzheimer’s candidate) showed preclinical anti-inflammatory and behavioral benefits across multiple preclinical studies and was presented at AAIC 2025. INM-755 advanced through Phase 1 and a Phase 2 EB study (19 of 20 enrolled) with reported safety and some efficacy signals. The company holds multiple patent families across product and manufacturing processes and continues CMC, GLP and scale-up activities. Major risks disclosed include clinical, regulatory, intellectual property, manufacturing, controlled-substance regulation, Nasdaq listing compliance and cybersecurity.
Form 8-K (Item 7.01 – Regulation FD): InMed Pharmaceuticals (Nasdaq: INM) announced it will present new pre-clinical data from its cannabinoid-based INM-901 program for Alzheimer’s disease at the Alzheimer’s Association International Conference (AAIC) 2025. The disclosure, dated 28 Jul 2025, is being furnished—not filed—so it carries no liability under Exchange Act §18 and will not be automatically incorporated into other SEC filings.
No financial results, guidance, or transactional details accompany the notice; the company simply alerts investors to an upcoming scientific presentation. Exhibit 99.1 (news release) and Exhibit 104 (XBRL cover data) are provided as furnished exhibits.
Because the information is limited to a pipeline update and occurs at the pre-clinical stage, any commercial or financial impact remains undetermined within the filing.
InMed Pharmaceuticals has announced promising new preclinical data for their drug candidate INM-901 on June 24, 2025. The research demonstrates significant reduction in inflammation in ex vivo models of neuroinflammation, strengthening the compound's potential as a therapeutic treatment for Alzheimer's disease.
Key points from the 8-K filing:
- The announcement falls under Regulation FD Disclosure (Item 7.01)
- The company is classified as an emerging growth company
- Common shares trade on Nasdaq under symbol INM
- The disclosure is being furnished rather than "filed" under SEC regulations
This development represents a significant milestone in InMed's neurodegenerative disease pipeline, though specific efficacy data and trial details were not disclosed in the filing. The news was signed off by President & CEO Eric A Adams.